Industry Sponsored Symposia

​​​​​​​WEDNESDAY, APRIL 6, 2016

Hall MP3&4, 13:30-15:30

The Interplay of T-cells and B-cells in Autoimmune Disease​

Sponsored by Bristol Myers Squibb

Bristol Myers Squibb GmbH

ChairpersonPiercarlo Sarzi PuttiniItaly

13:30-13:35 Introduction
                       Piercarlo Sarzi PuttiniItaly

13:35-14:05 T-cells, B-cells and Autoantibodies in Autoimmune Disease
                       Jens ThielGermany

14:05-14:35 Autoantibodies and Joint Destruction in Autoimmune Disease
                       Georg SchettGermany

14:35-15:05 Novel Therapy Strategies in the Treatment of Autoimmune Disease
                       Roberto CaporaliItaly

15:05-15:30 Question and Answer Session, Wrap up and Closing
                       Piercarlo Sarzi PuttiniItaly
                       Jens ThielGermany
                       Georg Schett, Germany
                       Roberto CaporaliItaly


Hall 4, 15:30-17:30

For The Achievement of Optimal Effectiveness by Novel Treatment Strategy with IL-6 Signaling Targeted Therapy in RA​​

Sponsored by Chugai

Chugai Pharmaceuticals Co.LTD

Chairpersons: Takao Koike, Japan 
                          Kazuhiko YamamotoJapan

15:30-15:35 Opening remarks: overview of Tocilizumab
                       Takao KoikeJapan

15:35-16:00 Cumulative safety data for Tocilizumab
                        Tatsuya Atsumi, Japan

16:00-16:25 Clinical, structural, and functional  efficacy of Tocilizumab
                        Yoshiya Tanaka, Japan

16:25-16:55 The importance of IL-6 signaling inhibition from the translational research
                        Tsutomu TakeuchiJapan​

16:55-17:25 The relationship between bone loss and inflammatory cytokine in RA
                        Georg Schett, Germany

17:25-17:30 Closing remarks: future treatment​ of IL-6 signal inhibition
                       Kazuhiko YamamotoJapan


THURSDAY, APRIL 7, 2016

Hall MP3&4, 12:30-14:00

Sponsored by Theradiag

Theradiag

Chairperson:​ M. Philippe LestageFrance

12:30-12:45 The trend for serological diagnosis of rheumatic diseases in China
                       Xiaofeng ZengChina

12:45-12:50 Q & A

12:50-13:15 The clinical performance of BioCLIA, a novel, automated and random-accessed Chemiluminescence immunoassay, in serological diagnosis of SLE patients and ANA screening in healthy individuals
                      Jieruo GuChina

13:15-13:20 Q & A

13:20-13:45 The development and evaluation of BioCLIA, a novel, automated and random-accessed chemiluminescence immunoanalyser for Autoantibody detection
                      Charles Lee

13:45-13:50 Q & A  


FRIDAY, APRIL 8, 2016

Hall MP3&4, 12:30-14:00​

Health Economics of ANA Screening ​

Sponsored by Inova Diagnostics

Inova Diagnostics Inc.

ChairpersonsMichael MahlerUSA 
                          Eckart MummertUSA

12:30-13:10 An approach to prevention of SLE: economics and diagnostic testing
                       Marvin FritzlerCanada

13:15-13:35 Anti-DFS70 Antibodies: A useful biomarker in a pediatric case with suspected autoimmune disease
                       Martina FabrisItaly

13:40-14:00 Immunoadsorption of DFS70 antibodies during ANA screening reduces "false positive" results
                       Nicola BizzaroItaly


SATURDAY, APRIL 9, 2016

Hall MP3&4, 12:30-14:00​

Immunoglobulin therapy in autoimmune diseases: what do we expect?​

Sponsored by LFB 
LFB Biomedicaments

ChairpersonsAbdulgabar Salama​, Germany
                          Francesco RodeghieroItaly

12:30-12:55 Quality and Clinical Safety of Immunoglobulin Therapies: Regulatory viewpoint
                       Jacqueline Kerr*Germany

13:00-13:25 Are all human intravenous immunoglobulin (IVIg) the same?
             - How can the characteristics of IVIg improve tolerability in patients?
               Srini KaveriINSERM (Paris) / CNRS (India)
              - New insights in IVIg development process
                Philippe Paolantonacci, LFB, France

13:30-13:55 Management of ITP: are we comfortable with our knowledge?
                       Francesco Rodeghiero, Italy

* Important: Dr Kerr is not sponsored by LFB and has no disclosures with the pharmaceutical company.​

Keep Me Updated